Omnipod 5 from Insulet Corp. - tubeless pump that talks to CGMs

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-23, 00:53. Details in the imprint.

Omnipod 5 sits flat on the skin like a rounded white pebble, no tubing in sight, just a quiet LED blink before it starts delivering insulin. Parents that product chief Bret Christensen talks to often describe that first tubeless night as oddly calm.

How Omnipod 5 works day to day

Omnipod 5 is a disposable, wearable pod that delivers insulin for up to 72 hours, controlled by either a dedicated controller or a compatible smartphone app. Each pod holds up to 200 units of U-100 insulin, enough for many users to get through three days.

The pod talks via Bluetooth to a continuous glucose monitor and adjusts basal insulin automatically based on CGM readings, aiming to stay near a user-set glucose target. The system can also deliver manual boluses for meals, so users still interact with food entries but less with fine-tuning overnight doses.

Automation and algorithm inside

Insulet uses its SmartAdjust technology, which updates insulin delivery every five minutes using CGM data and past insulin-on-board to reduce time spent high and low. In pivotal trials, people with type 1 diabetes on Omnipod 5 increased time in range while cutting hypoglycemia compared with prior therapy.

Endocrinologist Jennifer Sherr, who has presented trial data, highlighted that many participants woke up with noticeably flatter glucose curves, something families feel immediately when breakfast no longer starts with a correction dose. For users, the algorithm is invisible - they just see smoother trend lines on screen.

Comfort, wear and daily annoyances

Because the pod is tubeless and waterproof to typical shower depths, users can shower or sleep without worrying about kinking infusion sets or catching tubing on a door handle. On the flip side, the pod is bulkier than a slim infusion set and sits visibly under fitted clothing.

Adhesive is another recurring theme in patient forums, with some describing very secure wear even in summer heat while others need extra overpatches for sports. When a pod finally times out after three days, the device beeps and the user peels off a small plastic shell roughly the size of a large coin purse.

Who Omnipod 5 targets

Omnipod 5 primarily targets people with type 1 diabetes who want automated insulin delivery without being tethered to a traditional pump and tubing. It also appeals to parents of younger children, where fewer night-time wake-ups for corrections matter more than anything else.

Insulet emphasizes that Omnipod pods are disposable, with no upfront pump hardware purchase, which can make entry easier for some insured users compared with conventional pump systems that require a multi-year device commitment. In practice, total costs still depend heavily on reimbursement and copay rules in each market.

Where it is sold and priced

Omnipod 5 is commercially available in the United States and selected international markets, including parts of Europe, via diabetes clinics and specialized pharmacies. Insulet sells pods in multi-pack boxes, and pricing varies significantly by country and insurance coverage.

In the US, Omnipod 5 is offered through pharmacy channels, which Insulet CEO James Hollingshead has called a consistent way to lower upfront barriers compared with durable medical equipment channels. For Germany, availability still runs mainly via specialist diabetes centers and selected pharmacies, where reimbursement decisions shape real-world uptake.

What it means for the stock

For Insulet, Omnipod 5 is more than a single SKU - it is the platform that anchors growth expectations in automated insulin delivery. Insulet shares (ISIN US45784P1012) trade on Nasdaq under the ticker PODD, and analysts routinely frame earnings discussions around Omnipod adoption.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.